Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

This study is testing a combination of two drugs — zanzalintinib and eribulin — for people with advanced soft tissue sarcomas, specifically liposarcoma (fat tissue cancer) or leiomyosarcoma (smooth muscle cancer). Both cancers are difficult to treat once they've spread, and researchers are looking for more effective options. **You may be eligible if...** - You are 18 or older - You have been diagnosed with unresectable or metastatic leiomyosarcoma or a type of fat tissue sarcoma (adipocytic sarcoma) - Your cancer has progressed on at least 1 prior therapy, but you have received no more than 4 prior treatments - You have measurable cancer on imaging - Your blood counts, liver, and kidney function are adequate - You are in reasonably good overall health (ECOG 0–1) **You may NOT be eligible if...** - You have received more than 4 prior lines of cancer treatment - Your cancer has not progressed after any prior therapy - You have untreated cancer in the brain - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.